| Devatis AG - Ruxolitinib Devatis 15 mg, Tabletten | | 70478 | | 03 | | Ruxolitinib Devatis 15 mg | | Tabletten | | L01EJ01 | | Ruxolitinib | | 24.08.2026 | | |
| | Composition | | ruxolitinibum 15 mg ut ruxolitinibi hemifumaras, lactosum monohydricum 224.5365 mg, hydroxypropylcellulosum, povidonum K 30, carboxymethylamylum natricum A corresp. natrium 0.60 mg, silica colloidalis anhydrica, cellulosum microcristallinum, magnesii stearas, pro compresso. | | Packungsbestandteile | | Tablets | | | | Active Agent | Dose |
|---|
| Ruxolitinibum | 15 mg |
| | | | Inactive agents | Dose |
|---|
| Carboxymethylamylum Natricum A | | | Cellulosum Microcristallinum | | | Hydroxypropylcellulosum | | | Lactose Monohydrate | 224.5365 mg | | Magnesii Stearas | | | Povidonum K | 30 | | Pro Compresso | | | Silica Colloidalis Anhydrica | |
|
| | Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
|---|
| 003 | 56 | | | A | | Yes |
|
|
